77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by ...

Narcolepsy, with or without cataplexy, can have a substantial detrimental effect on well-being and quality of life. Because there is no cure for this condition, current treatments aim to improve ...

Oveporexton is designed to promote wakefulness and reduce abnormal REM-sleep-like phenomena, including cataplexy, in patients with NT1.

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of ...

Alixorexton at all doses demonstrated significant improvements from baseline in mean sleep latency compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (ALKS) (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the ...